Keros Therapeutics (KROS) AI Stock Analysis

• Market Cap: $529.20M
• Dividend Yield: N/A
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): 11.4
• Beta (1Y): 0.61
• Revenue Growth: 37798.31%
• EPS Growth: N/A
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 30,466,068
• 10 Day Avg. Volume: 1,385,063
• 30 Day Avg. Volume: 1,219,637
• PEG Ratio: 0.82
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 166.94
• P/FCF Ratio: -3.64
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: -0.14
• Enterprise Value/Gross Profit: -0.14
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $20.80
• Price Target Upside: 18.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 1.83
• Revenue Forecast (FY): $244.68M

• Rating: 73 Outperform
• Price Target: $18.00 ▲(2.56% Upside)

Keros Therapeutics receives a strong overall score driven by its solid financial performance and attractive valuation. The technical analysis indicates positive momentum, supporting the stock's potential for appreciation. However, historical volatility in financials suggests some caution is warranted.

Positive Factors

Strong Revenue Growth

The significant revenue beat indicates strong demand and successful execution of strategic initiatives, enhancing long-term growth prospects.

Strategic Partnerships

The partnership with Takeda provides financial resources and market access, supporting the development and commercialization of Keros' products.

Pipeline Advancement

Progress in clinical trials strengthens Keros' product pipeline, potentially leading to new revenue streams and market expansion.

Negative Factors

Historical Revenue Volatility

Past revenue volatility suggests potential instability, which could challenge consistent growth and investor confidence in the long term.

Cash Flow Volatility

Volatile cash flows can impact operational stability and limit the company's ability to invest in growth opportunities consistently.

R&D and Investment Costs

High R&D and investment costs, while necessary for growth, may pressure financials and delay profitability, affecting long-term sustainability.

Keros Therapeutics Business Overview & Revenue Model

Company Description

Keros Therapeutics, Inc. (KROS) is a biotechnology company focused on developing innovative therapies for rare hematological and endocrine disorders. The company is engaged in the discovery and development of novel treatments that target the pathways involved in these conditions, with core products aimed at addressing unmet medical needs in conditions such as anemia and other related disorders.

How the Company Makes Money

Keros Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may engage in partnerships and collaborations with larger pharmaceutical firms, which can provide funding and resources for research and development in exchange for shared profits or licensing agreements. Additionally, Keros Therapeutics may receive milestone payments as it progresses through various stages of clinical trials and regulatory approvals. If successful, the company would earn revenue from product sales once its therapies are approved and brought to market.

Keros Therapeutics Financial Statement Overview

Summary

Keros Therapeutics shows a positive financial trajectory with improved profitability and strong balance sheet metrics. The company has effectively managed costs and leverage, resulting in better margins and financial stability. However, historical volatility in revenue and cash flows suggests the need for cautious optimism moving forward.

Income Statement

Keros Therapeutics has shown a significant improvement in its income statement metrics over the TTM period. The gross profit margin is exceptionally high at 99.56%, indicating strong cost management. The net profit margin has turned positive at 8.06%, a significant improvement from previous negative margins, reflecting better profitability. Revenue growth rate of 5.96% in the TTM suggests a positive trajectory, although the company has experienced volatility in revenue growth in prior years.

Balance Sheet

The balance sheet of Keros Therapeutics is strong, with a low debt-to-equity ratio of 0.025, indicating minimal leverage and financial risk. The return on equity (ROE) is modest at 2.96%, showing a positive return to shareholders. The equity ratio is healthy, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

The cash flow statement shows a robust free cash flow growth rate of 64.06% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is 1.59, suggesting strong cash conversion. However, historical cash flow volatility and negative cash flows in prior years highlight potential risks in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	246.72M	3.55M	151.00K	0.00	20.10M	0.00
Gross Profit	245.62M	3.55M	151.00K	0.00	20.10M	-605.00K
EBITDA	82.39M	-185.82M	-152.18M	-104.00M	-56.35M	-44.92M
Net Income	64.45M	-187.35M	-152.99M	-104.68M	-58.74M	-45.36M
Balance Sheet
Total Assets	742.78M	615.89M	370.02M	306.78M	255.25M	269.44M
Cash, Cash Equivalents and Short-Term Investments	693.47M	559.93M	331.15M	279.05M	230.04M	265.88M
Total Debt	17.43M	18.86M	14.44M	13.27M	1.09M	899.00K
Total Liabilities	39.20M	44.33M	37.81M	29.36M	12.08M	7.72M
Stockholders Equity	703.58M	571.55M	332.21M	277.42M	243.17M	261.72M
Cash Flow
Free Cash Flow	87.08M	-162.80M	-126.97M	-71.30M	-63.17M	-37.19M
Operating Cash Flow	88.79M	-160.87M	-124.51M	-70.06M	-62.15M	-36.89M
Investing Cash Flow	-1.71M	-1.93M	-2.46M	-1.24M	-1.02M	-294.00K
Financing Cash Flow	75.70M	391.82M	178.96M	120.31M	28.55M	296.04M

Keros Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Positive. The current price of 17.55 is above the 20-day moving average (MA) of 16.10, above the 50-day MA of 15.76, and above the 200-day MA of 13.85, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 58.48 is Neutral, neither overbought nor oversold. The STOCH value of 79.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KROS.

Keros Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	73 Outperform	$529.20M	11.38	10.43%	―	37798.31%	―
GYRE	55 Neutral	$658.49M	444.79	8.06%	―	―	―
PVLA	52 Neutral	$830.14M	-5.95	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRIX	51 Neutral	$1.30B	―	-65.35%	―	48.32%	-1.91%
BCAX	48 Neutral	$824.47M	―	-26.64%	―	―	―
KALV	45 Neutral	$692.99M	―	―	―	―	-13.14%

Keros Therapeutics Corporate Events

Keros Therapeutics Reports Strong Revenue Growth

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focusing on developing novel therapeutics for disorders related to the transforming growth factor-beta family of proteins. The company is advancing treatments for neuromuscular diseases and cytopenias, including anemia and thrombocytopenia.

Keros Therapeutics Announces $375M Capital Return Program

On October 15, 2025, Keros Therapeutics announced a $375 million capital return program, including repurchasing shares from ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million. This move, alongside a planned tender offer for additional shares, reflects Keros’ confidence in its financial position and clinical strategy, particularly for its KER-065 program. The resignations of board members Tomer Kariv and Ran Nussbaum were also announced, with Jean-Jacques Bienaimé appointed as the new Chair of the Nominating and Corporate Governance Committee. The company plans to distribute part of its Takeda licensing revenue to shareholders, aiming to enhance long-term stockholder value.

The most recent analyst rating on (KROS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics Presents Promising Phase 1 Trial Data

On September 8, 2025, Keros Therapeutics announced the presentation of additional clinical data from its Phase 1 trial of KER-065 at the American Society of Bone and Mineral Research 2025 Annual Meeting. The trial, conducted in healthy male volunteers, showed that KER-065 was generally well-tolerated and demonstrated promising results in increasing bone mineral density, suggesting potential benefits for patients with Duchenne muscular dystrophy and bone disorders. The data indicated that KER-065 could balance osteoblast and osteoclast activity, with improvements in bone biomarkers and sustained increases in bone mineral density observed through Day 141.

The most recent analyst rating on (KROS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics CEO to Speak at Healthcare Conferences

On August 28, 2025, Keros Therapeutics announced that its President and CEO, Jasbir Seehra, will participate in two upcoming healthcare conferences. These events include a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025, and a corporate presentation at the H.C. Wainwright Global Investment Conference on September 9, 2025. The participation in these conferences highlights Keros’ ongoing efforts to engage with the investment community and stakeholders, potentially impacting its industry positioning and visibility.

The most recent analyst rating on (KROS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics Gains FDA Orphan Drug Designation

On August 20, 2025, Keros Therapeutics announced that the U.S. FDA granted Orphan Drug designation to KER-065 for treating Duchenne muscular dystrophy (DMD). This designation highlights the unmet medical need for DMD patients and marks a significant milestone for Keros as they advance KER-065 into a Phase 2 clinical trial. The Orphan Drug status offers potential benefits like tax credits and market exclusivity, which could enhance Keros’ market positioning and operational strategy in developing treatments for rare diseases.

The most recent analyst rating on (KROS) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Keros Therapeutics Reports Strong Revenue Growth

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with its principal offices located in Lexington, Massachusetts.

Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks

Keros Therapeutics, Inc. faces significant risks from its corporate restructuring announced in May 2025, which aimed to cut costs by reducing its workforce by 45%. While the company anticipates annual savings of $17 million, these projections are uncertain and could be undermined by unforeseen challenges, potentially impacting its financial health. The restructuring might disrupt operations, lower employee morale, and hinder compliance with legal requirements, posing further risks to its ability to attract and retain essential personnel. Such disruptions could adversely affect the development of KER-065 and ongoing collaborations, threatening the company’s strategic objectives.